Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Will Answer FDA “Complete Response” Letter For Cervarix In Second Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee review of the human papilloma virus vaccine expected, CEO Garnier says during year-end earnings call.

You may also be interested in...



GSK’s Responds To FDA On Cervarix, Will Augment BLA With More Efficacy Data

Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.

GSK’s Responds To FDA On Cervarix, Will Augment BLA With More Efficacy Data

Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.

Merck Receives FDA “Complete Response” On Gardasil For Women 27-45

Firm also receives complete response to its sBLA for cross-protection.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel